Inventera Q1 2026 Report: KOSDAQ IPO Completed, Clinical Pipeline Advancing, Solid Financial Structure

Completed KOSDAQ listing on April 2, 2026, net proceeds of ~18.8 billion KRW from IPO
Key pipelines: INV-002 in Phase 3 (Korea), US FDA Phase 2b IND approved; INV-001 in Phase 2a (Korea), US Phase 2 IND approved; INV-003 in IND-enabling stage
18 registered global patents (5 domestic, 13 overseas), 37 pending applications
Exclusive sales agreement with Partner A for Korea, China, Japan, SE Asia (Mar 2024); manufacturing agreement with Partner B for API
Q1 2026: Zero revenue, operating loss 1.91 billion KRW, net loss 1.82 billion KRW
Cash & cash equivalents 0.66 billion KRW but other financial assets 31.03 billion KRW; total assets 32.65 billion, equity 31.60 billion
Net debt zero, total liabilities only 1.05 billion; very low leverage
Credit rating B0 (NICE, as of Dec 31, 2024)
No shareholder return plans (dividend, share buyback/cancellation)